Literature DB >> 12956197

Treatments of tinea pedis.

Aditya K Gupta1, Melody Chow, C Ralph Daniel, Raza Aly.   

Abstract

The severity of tinea pedis infection determines the course of treatment required. Mild infections may be resolved using a topical agent. More severe presentations (eg, dermatophytosis complex) may require treatment that eliminates the bacterial and fungal infection. Some topical monotherapies may exhibit both antifungal and antibacterial activity. In other instances, it may be necessary to combine an antifungal agent with an antibacterial agent. If inflammation is present, an agent with known anti-inflammatory action may need to be used. The chronic presentation of tinea pedis (dry type) sometimes does not respond well to topical therapy. In such instances, systemic antifungal therapy is required to ensure that adequate concentrations of the therapeutic agent are present at the site of infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12956197     DOI: 10.1016/s0733-8635(03)00032-9

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  5 in total

1.  Fabrication of Highly Deformable Bilosomes for Enhancing the Topical Delivery of Terconazole: In Vitro Characterization, Microbiological Evaluation, and In Vivo Skin Deposition Study.

Authors:  Shaimaa Mosallam; Nermin M Sheta; Ahmed Hassen Elshafeey; Aly Ahmed Abdelbary
Journal:  AAPS PharmSciTech       Date:  2021-02-14       Impact factor: 3.246

Review 2.  Advanced Vesicular Systems for Antifungal Drug Delivery.

Authors:  Shaimaa Mosallam; Rofida Albash; Manar Adel Abdelbari
Journal:  AAPS PharmSciTech       Date:  2022-07-28       Impact factor: 4.026

Review 3.  Update in antifungal therapy of dermatophytosis.

Authors:  Aditya K Gupta; Elizabeth A Cooper
Journal:  Mycopathologia       Date:  2008-05-14       Impact factor: 2.574

Review 4.  Vesicular nanocarrier based treatment of skin fungal infections: Potential and emerging trends in nanoscale pharmacotherapy.

Authors:  Shivani Verma; Puneet Utreja
Journal:  Asian J Pharm Sci       Date:  2018-08-16       Impact factor: 6.598

5.  Development of terbinafine solid lipid nanoparticles as a topical delivery system.

Authors:  Ying-Chen Chen; Der-Zen Liu; Jun-Jen Liu; Tsung-Wei Chang; Hsiu-O Ho; Ming-Thau Sheu
Journal:  Int J Nanomedicine       Date:  2012-08-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.